Investidor Profissional Gestao de Recursos Ltda. Sells 5,140 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Investidor Profissional Gestao de Recursos Ltda. reduced its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 81.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,164 shares of the medical research company's stock after selling 5,140 shares during the quarter. Thermo Fisher Scientific accounts for approximately 0.3% of Investidor Profissional Gestao de Recursos Ltda.'s investment portfolio, making the stock its 17th biggest holding. Investidor Profissional Gestao de Recursos Ltda.'s holdings in Thermo Fisher Scientific were worth $720,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of TMO. International Assets Investment Management LLC increased its position in Thermo Fisher Scientific by 76,051.4% during the third quarter. International Assets Investment Management LLC now owns 1,416,416 shares of the medical research company's stock worth $876,152,000 after acquiring an additional 1,414,556 shares during the period. Capital World Investors boosted its stake in Thermo Fisher Scientific by 10.0% in the first quarter. Capital World Investors now owns 13,493,852 shares of the medical research company's stock valued at $7,842,762,000 after buying an additional 1,231,059 shares in the last quarter. Swedbank AB bought a new stake in shares of Thermo Fisher Scientific during the first quarter worth $705,636,000. Ameriprise Financial Inc. increased its stake in shares of Thermo Fisher Scientific by 32.2% in the second quarter. Ameriprise Financial Inc. now owns 2,481,257 shares of the medical research company's stock valued at $1,372,157,000 after buying an additional 604,895 shares during the period. Finally, Point72 Asset Management L.P. raised its position in Thermo Fisher Scientific by 743.6% during the 2nd quarter. Point72 Asset Management L.P. now owns 336,537 shares of the medical research company's stock worth $186,105,000 after purchasing an additional 296,646 shares during the last quarter. Institutional investors own 89.23% of the company's stock.

Insider Activity

In related news, SVP Michael A. Boxer sold 2,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, October 25th. The shares were sold at an average price of $560.16, for a total value of $1,120,320.00. Following the sale, the senior vice president now owns 12,736 shares of the company's stock, valued at approximately $7,134,197.76. The trade was a 13.57 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Gianluca Pettiti sold 300 shares of the firm's stock in a transaction on Friday, October 25th. The stock was sold at an average price of $560.16, for a total value of $168,048.00. Following the completion of the sale, the executive vice president now directly owns 16,663 shares of the company's stock, valued at $9,333,946.08. This represents a 1.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 37,150 shares of company stock valued at $20,651,865 in the last ninety days. 0.34% of the stock is currently owned by insiders.

Analyst Ratings Changes

TMO has been the subject of a number of analyst reports. Wells Fargo & Company lowered their price objective on Thermo Fisher Scientific from $670.00 to $660.00 and set an "overweight" rating for the company in a research report on Thursday, October 24th. Barclays decreased their price objective on shares of Thermo Fisher Scientific from $620.00 to $610.00 and set an "equal weight" rating for the company in a research report on Wednesday, October 23rd. Royal Bank of Canada decreased their price target on Thermo Fisher Scientific from $767.00 to $718.00 and set an "outperform" rating for the company in a report on Thursday, October 24th. Morgan Stanley lifted their target price on Thermo Fisher Scientific from $655.00 to $680.00 and gave the stock an "overweight" rating in a report on Friday, September 20th. Finally, Robert W. Baird dropped their target price on shares of Thermo Fisher Scientific from $632.00 to $622.00 and set an "outperform" rating on the stock in a research report on Thursday, October 24th. Four investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $649.33.

Thermo Fisher Scientific Stock Down 2.4 %

NYSE TMO traded down $12.38 on Monday, reaching $500.70. The company had a trading volume of 1,830,017 shares, compared to its average volume of 1,475,417. The company has a quick ratio of 1.26, a current ratio of 1.63 and a debt-to-equity ratio of 0.64. The stock has a market capitalization of $191.52 billion, a P/E ratio of 32.17, a P/E/G ratio of 3.39 and a beta of 0.79. The company's fifty day moving average is $586.43 and its 200 day moving average is $582.39. Thermo Fisher Scientific Inc. has a 52-week low of $465.90 and a 52-week high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share for the quarter, topping the consensus estimate of $5.25 by $0.03. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. The business had revenue of $10.60 billion for the quarter, compared to analysts' expectations of $10.63 billion. During the same period in the previous year, the company earned $5.69 earnings per share. The firm's revenue for the quarter was up .2% compared to the same quarter last year. Sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 21.67 earnings per share for the current fiscal year.

Thermo Fisher Scientific announced that its board has authorized a stock repurchase plan on Friday, November 15th that allows the company to repurchase $4.00 billion in outstanding shares. This repurchase authorization allows the medical research company to reacquire up to 2% of its shares through open market purchases. Shares repurchase plans are often an indication that the company's leadership believes its stock is undervalued.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 15th. Shareholders of record on Friday, December 13th will be given a $0.39 dividend. The ex-dividend date is Friday, December 13th. This represents a $1.56 annualized dividend and a yield of 0.31%. Thermo Fisher Scientific's dividend payout ratio is currently 9.78%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.